Research programme: cutaneous lupus erythematosus therapy - MediQuest Therapeutics

Drug Profile

Research programme: cutaneous lupus erythematosus therapy - MediQuest Therapeutics

Alternative Names: Cutaneous lupus therapy - MediQuest Therapeutics; MQX-1505

Latest Information Update: 31 May 2010

Price : $50

At a glance

  • Originator MediQuest Therapeutics
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Cutaneous lupus erythematosus

Most Recent Events

  • 14 Jul 2006 This programme is still in active development
  • 20 Jul 2004 Preclinical trials in Cutaneous lupus erythematosus in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top